The most aggressive cancers were the ones more likely to express ROR1. ??That suggests ROR1 could be a good target for treating the most aggressive kinds of breast cancer, particularly the ones that lack expression of hormone receptors or the marker HER2/neu, which already can be targeted by monoclonal antibodies,?? Kipps said.